CytomX Therapeutics Announces First Quarter 2025 Financial Results and Provides Business Update
Provided By GlobeNewswire
Last update: May 12, 2025
- Announced Positive Interim Data From Ongoing Phase 1 Dose Escalation Study of EpCAM Antibody Drug Conjugate (CX-2051) in Patients with Advanced Colorectal Cancer (CRC) -
Read more at globenewswire.comNASDAQ:CTMX (10/10/2025, 3:33:10 PM)
3.28
-0.17 (-4.93%)
Find more stocks in the Stock Screener
CTMX Latest News and Analysis
